Precision Oncology Market Revenue, Leading Companies, Company Technology / Innovation, Diagnostic Adoption, Treatment Adoption Rates, Pricing Metrics, Supply Chain Performance, Competitive Positioning, and Industry Trends

Revenue, 2025

USD 133 Bn

Forecast Year, 2035

USD 338.89 Bn

CAGR, 2026 - 2035

11.33%

Report Coverage

Global

What is the Precision Oncology Market Size?

The global precision oncology market size accounted for USD 133 billion in 2025 and is predicted to increase from USD 146.24 billion in 2026 to approximately USD 338.89 billion by 2035, expanding at a CAGR of 11.33% between 2026 to 2035. Advances in genomic profiling and personalized cancer treatments drive the precision oncology market.

Precision Oncology Market Key Takeaways

• By Region, North America accounted for the largest revenue share of the precision oncology market in 2025.
• By Region, Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By product, the therapeutics segment registered its dominance over the global market in 2025.
• By product, the diagnostics segment is expected to witness the fastest growth in the market with a CAGR over the forecast period.
• By cancer type, the breast cancer segment dominated the global market in 2025.
• By cancer type, the lung cancer segment is expected to gain the highest market share with a CAGR between 2026 and 2035.
• By end-use, the hospitals & diagnostic laboratories segment held the largest revenue market in 2025.
• By end-use, the pharmaceutical & biotechnology companies segment is expected to show the fastest growth with a CAGR over the forecast period.

What is Precision Oncology?

Precision oncology is the molecular profiling of tumors to find changes that can be targeted. In layman's words, it's the science of tailoring a patient's treatment to the molecular characteristics of their cancer by using genetic information from the patient. An exciting period in the fight against cancer is being ushered in by the emergence of precision oncology and the development of more individualized and targeted treatment approaches.

Precision oncology is a dynamic, interesting field of study that is increasingly finding its way into conventional oncology practice. Improving patient outcomes is precision oncology's ultimate goal. Targeted therapy, which focuses on a specific genetic biomarker, is made possible by precision oncology. By protecting healthy cells and reducing side effects, targeted medicines can prevent cancer cells carrying that genetic biomarker from proliferating and developing.

Key AI Integration in the Precision Oncology Market

Integrating AI into precision oncology is transforming complex patient information, making it more precise and faster. Cancer AI platforms can process medical data, medical images, and genomic information, and identify patterns within the information that are relevant for diagnosis and therapy in the cancer context. Clinicians can use machine learning tools to choose therapies more tailored to the characteristics of each tumor and biomarkers. AI is also being applied in oncology to aid in determining future treatment and combination therapies.

Precision Oncology Market Growth Factors

The rising prevalence of cancer across the globe is anticipated to augment the growth of the precision oncology market during the forecast period. Additionally, the development of advanced technologies like next-generation sequencing technology is also likely to fuel the growth of the market in the near future. The increasing investment in discovering new diagnostics along with growing efforts by numerous players to develop medicines via rapid cycles of innovation to bring advances to patients more swiftly is further expected to support the market growth in the years to come.

Personalization has advanced beyond therapy selection and into the area of drug research to enhance health thanks to governmental investment, biotechnology advancements, and digitization of health profiles. Diagnostic, digital, and imaging advancements as well as a plethora of analytics tools operating across numerous institutions and stakeholders are what are powering this transition. Academic research workers have typically been in charge of biomarker discovery. The extensive clinical engagement in biomarker research is particularly intriguing. The prevalence of this trend has increased as research discoveries are put to use in the clinic more quickly.

Market Outlook

• Industry Growth Overview:
  The precision oncology market is experiencing significant growth, driven by rising cancer prevalence, advanced genomic tech, and demand for personalized treatments with fewer side effects, with diagnostics and therapeutics.
• Global Expansion:
  The precision oncology market expanded globally due to high R&D spending and supportive government initiatives. North America is dominant in the market due to growing cancer rates and tech advances.
• Major investors:
  Major investors include large pharma (Novartis, Roche, J&J), large asset managers like Blackstone, BlackRock, specialized venture capital/private equity firms (Arch Venture Partners, Orbimed, Casdin Capital), and major diagnostic/life science companies.

Strategic Growth Opportunities

• High-Growth Commercial Opportunities: Targeted therapies, companion diagnostics, liquid biopsies and genomic testing are areas of increasing demand, presenting good commercial opportunities. Solutions providers can benefit by creating cancer diagnostics and theragnostics platforms and by scaling personalised cancer-care services.
• Emerging Technology Opportunities: Artificial intelligence, machine learning, next-generation sequencing, digital pathology, and multi-omics technologies are offering new opportunities throughout the precision oncology landscape. Focusing on AI diagnostics, predictive analytics, and treatment selection, companies can distinguish themselves through their ability to provide personalized care.

Market Scope

Market Dynamics

Driver

Increasing demand for personalized medicine

The increasing demand for personalized medicine due to the benefits it offers is anticipated to augment the growth of the precision oncology market within the estimated timeframe. Patients are more engaged with their treatment plan as they receive more individualized information that enables them to make better health decisions. Other advantages of patient participation include better patient outcomes, more revenue for healthcare providers, and improved patient-therapist relationships. Patients with high levels of patient engagement and activation are more likely to stick with their physical therapy regimen. Patient activation is the degree to which a patient is knowledgeable, competent, and self-assured in controlling their own health.

Companies in the pharmaceutical and biotech industries have used various strategies to seize the benefits of personalized medicine. Others have chosen a "wait-and-watch" policy with targeted investments, while some have integrated these therapeutics into their business goal by integrating them into all processes. Since there is a great deal of ambiguity around many crucial issues, including the degree to which practitioners will adopt next-generation sequencing and other cutting-edge technology, diagnostics businesses have also investigated a variety of methods to personalized medicine. Additionally, in the present regulatory and reimbursement environment, diagnostics companies are still looking for ways to successfully capture value for their innovation. Thus, these factors are likely to contribute to the growth of the precision oncology market during the forecast period.

Restraints

Limited availability of precision treatments linked to biomarkers

A prerequisite for biomarker testing is the availability of precision medicines related to biomarkers since most doctors won't order tests unless the results can be used to guide treatment choices. Before medications that have been approved by regulatory agencies are released and added to national or regional reimbursement lists, there are often significant delays. For instance, according to the EFPIA's Patients W.A.I.T. indicator Survey, the average wait time for patients to receive treatments across the European Economic Area and EU is 504 days; however this time can vary from 127 days in Germany to over 823 days in Poland. Additionally, for the prescription of precision medicines in several nations, public funding is insufficient.

The root causes of delayed patient access to medications in various economies are obstacles to the readiness of the health system, challenges with the reimbursement process, differences in and a lack of clarity regarding the reimbursement criteria, as well as evidence gaps and a misalignment on value and price between decision-makers for reimbursement and pharmaceutical companies. Addressing this challenge is one of the key priorities since it is likely to limit the growth of the market.

Opportunities

Integration with other technologies

The integration of precision oncology with other technologies such as artificial intelligence, big data analytics, and digital health tools has the potential to improve patient outcomes and accelerate drug development. With technological breakthroughs, nanotechnology and artificial intelligence (AI) have been employed as tools to increase the precision of cancer treatment. The personalized precision medicine treatment for cancer patients has improved as a result of the significant advancement in obtaining patient data with better nanomaterial designs. Combining AI with nanotechnology has improved the accuracy of the rational design of diagnostic and treatment platforms. Definitive outcomes in nanomedicine which encompasses everything from biological and nanomaterial devices to nanoelectronic biosensors has also shown promise, with special praise going to the use of AI.

Reforms in AI and ML have led to the booming development of tools and algorithms that aid in the efficacy of treating cancer patients with customized precision medicine. The prediction obtained from the algorithms created by AI technologies to evaluate therapies is quite meticulous and gives a significant reduction in the likelihood of errors in terms of the prescribed treatment. Additionally, predictive analytics is essential for identifying people who are at a high risk of developing certain ailments and diseases, like cancer, and for creating individualized treatment strategies. Therefore, the rising implementation of various technologies is expected to create immense growth opportunities for the market in the years to come.

Impact of COVID-19:

The COVID-19 pandemic revealed the flaws and injustices in the world healthcare system, but it also had the potential to spark long-needed transformational reform. Not only did the covid-19 pandemic result in dramatic drops in cancer diagnoses, but it also markedly decreased the use of biomarker testing, which is frequently essential for choosing the best course of treatment for many common malignancies. Additionally, patients were naturally hesitant or unwilling to seek out regular general and specialized care during the pandemic, which frequently includes essential preventative cancer tests. Although there have long been significant obstacles preventing the advancement of precision medicine oncology, covid-19 has also brought to light the urgent need for accelerated development of cancer care technologies and greater international cooperation on shared health threats. As a result, some of these challenges will be easier to overcome in a post-covid world.

Segment Insights

Product Insights

On the basis of product, the therapeutics segment held largest revenue share of 72% in 2023. The development of various targeted drug therapy such as angiogenesis inhibitors & monoclonal antibodies and immunotherapies are expected to contribute to the segment growth of the precision oncology market during the forecast period. In order to kill a cancer cell, monoclonal antibodies may transfer drug- or drug-containing molecules into or onto the cancer cell. Examples include cetuximab (for some head, colon, lung, and neck cancers), trastuzumab (certain breast malignancies), and alemtuzumab (certain chronic leukaemias). Furthermore, extensive ongoing research in these types of therapies is also likely to support the segment growth of the precision oncology market during the forecast period. Additionally, rising awareness about these therapies amongst physicians as well as patients is further anticipated to augment the growth of the segment within the estimated timeframe.

The diagnostics segment is expected to grow steadily during the forecast period with the rise of precision-based cancer testing. Molecular diagnostic technologies are used to identify certain genetic changes linked to a variety of cancers in the healthcare area. Companion diagnostics are becoming more available for use to guide targeted treatment for patients.

Cancer Type Insights

The lung cancer segment is expected to witness notable growth due to the use of molecular testing and targeted drugs. Genetic testing is being used to help identify the mutations that could help to decide which targeted drugs are advised for single patients. The identification of specific tumougenomic characteristics through the use of molecular profiling is helping health care professionals to choose treatments for individual patients.

The blood cancer segment is expected to grow steadily, as molecular profiling and the development of targeted drugs will increase. Blood tests and similar tests are available to help diagnose changes in the genes or molecules that have been linked to some cancers such as leukemia, lymphoma, or multiple myeloma. Therapies targeting molecular targets are further contributing to the push of precision oncology.

The prostate cancer segment is projected to witness stable growth during the forecast period as a result of personalized treatment options. The use of biomarker testing is increasing in importance as a tool to diagnose patients who may benefit from certain therapies. Genomic profiling is improving the understanding of molecular features of prostate tumours.

Based on the cancer type, the breast cancer segment held the largest market share of 42% in 2023. One of the first medical fields to use precision medicine is cancer care. There are various genetic and nongenetic testing for breast cancer that can aid in individualized treatment. Some genetic tests are specifically designed to assess hereditary risk, which means they examine the individual's genetic profile to assess their lifelong risk of acquiring breast cancer or other cancers. The growth of the segment is being supported by the increasing research and development of precision medicines for breast cancer along with rising strategic moves by various key players. For instance, in March 2022, in order to develop complete molecular profiling, Avera Health (Avera) and Theralink Technologies established a strategic alliance. As a result, Avera Health's physicians and patients will get access to data-driven insights that guide tailored cancer treatments. In addition, the introduction of advanced technologies for DNA sequencing is also expected to drive the segment growth of the market.

End-use Insights

Which Factors Contributed to the Hospitals & Diagnostic Laboratories Segment Growth in the Precision Oncology Market?

The hospitals & diagnostic laboratories segment dominated the market in 2025, due to its major contribution to cancer diagnosis and therapy. Molecular testing papers and genomic profiling will be more widespread in hospitals and will be used to help patients make informed decisions. Diagnostic labs provide more specific testing, which allows for detection of biomarkers and genetic changes.

The pharmaceutical & biotechnology companies segment is expected to witness notable growth because of rising investment in targeted cancer therapies. Larger studies are being conducted to find specific molecules that are associated with particular types of cancer. Precision oncology can help to classify the patient population that is able to be addressed with genetically specific therapy.

The healthcare data companies segment is expected to grow steadily, with an increase in genomic and clinical data generated in the care of cancer. These companies provide the platforms for gathering, structuring, and analyzing very complex and detailed healthcare information. With more use of AI, even the big data regarding oncology is being processed even better. Precision Medicine, which requires information about patients that is sensitive, is increasingly important, so they have secure data management solutions.

Regional Insights

What is the U.S. Precision Oncology Market Size?

The U.S. precision oncology market size reached USD 40.03 billion in 2025 and is expected to be worth around USD 104.36 billion by 2035, at a CAGR of 10.06% between 2026 to 2035.

North America Increasing prevalence of cancer

North America held the largest revenue share of 43% in 2023. US accounted for the largest share in the North America precision oncology market. This is owing to the increasing prevalence of cancer in the region. According to CDC, around 1,752,735 new cancer cases were reported in the US in 2019 and approximately 599,589 people died due to cancer. Also, approximately 439 new cancer cases were reported for every 100,000 people along with 146 people died of cancer. Thus, this is increasing the demand for precision oncology therapies in the region.

Furthermore, the presence of key competitors such as Thermo Fisher Scientific Inc., Illumina, Inc. and Invitae Corporation, among others along with rising research funding in the region have also contributed to the growth of the market. Additionally, the availability of developed healthcare infrastructure is likely to support the regional growth of the precision oncology market during the forecast period.

U.S. Precision Oncology Market Trends

In the U.S., numerous lifestyle factors such as obesity, physical inactivity, diet, and environmental issues like air pollution contribute to higher cancer rates. By 2025, there are projected to be 2,041,910 new cancer cases and 618,120 deaths. Healthcare providers in the U.S. are increasingly shifting from standard chemotherapy to personalized treatments, including CAR-T cell therapies and monoclonal antibodies.

Asia Pacific investment in the healthcare infrastructure

Asia-Pacific is expected to grow at the fastest CAGR during the forecast period. The increasing investment in the healthcare infrastructure along with research and development is anticipated to augment the regional growth of the precision oncology market during the forecast period. Furthermore, the growing aging population along with the increasing demand for personalized medicine for effective treatment is also likely to support the regional growth of the market in the years to come. Additionally, the advancement in gene mapping technologies and rising focus on the development of biotechnology is also expected to fuel the market growth in the region.

India Precision Oncology Market Trends

In India, the incidence of cancer is rising alarmingly, with certain types becoming more prevalent due to a complex interplay of genetic, lifestyle, dietary, environmental, and healthcare factors. India has a poor cancer detection rate of 29%, with only 15% and 33% of breast, lung, and cervical cancers being diagnosed in stages 1 and 2, respectively.

Europe: Increasing government initiative

In Europe, government initiatives are expanding. Programs like Europe's Beating Cancer Plan and the EU Health Data Space are creating roadmaps for standardizing genetic testing and enabling cross-border data sharing. Several countries, including France, England, and Germany, have launched large genomic programs to harness genomic medicine's potential to improve health, drive scientific innovation, and boost the economy.

The UK Precision Oncology Market Trends

The UK is advancing in genomic research, especially in precision oncology, backed by extensive government investment in diagnostics such as Community Diagnostic Centres, world-class research institutions like Cancer Research UK, robust genomic initiatives, and strategic collaborations with industry, all supporting the development and implementation of personalized cancer therapies and diagnostics.

Key Trends in the Precision Oncology Market in Latin America

Latin America is expected to witness significant growth in the market as the demand for advanced cancer diagnostics services and personalized treatment increases. Increased incidence rates for cancer are putting higher demand on the need for disease characterization with adequate accuracy and targeted treatment. The penetration of precision oncology is promoted in major markets by the development of healthcare facilities. The pharmaceutical and diagnostic firms are also expanding their operation on an increasing scale throughout the region.

Brazil Market Trends

Brazil precision oncology market is anticipated to grow significantly, due to its high population of patients with cancer and rising demand for advanced treatment. The molecular diagnostic evolution is making its way into healthcare practices and becoming increasingly common as a way to inform more personalized treatment options. Enabling progress in improving the infrastructure for genomic testing is making it easier to provide services for precision medicine.

Growth of the Middle East and Africa in the Precision Oncology Market

The Middle East and Africa region is expected to witness significant growth in the market driven by rising adoption of advanced cancer diagnosis and personalized care. The countries are taking long strides with regard to enhancing the oncology infrastructure and diagnostic capabilities on account of a rise in health expenditure rates. Collaborative efforts between international partners are working to broaden available genomic and targeted treatment and access.

Saudi Arabia Market Trends

Saudi Arabia market is anticipated to grow significantly, driven by the rising investments in healthcare and modernization of cancer treatment services. Rapid growth of specialised healthcare facilities is driving the use of cutting-edge technologies in diagnostics and genomics. Increasingly, healthcare providers are looking into molecular profiling to determine more personalized treatments. Medical technologies being chosen and used are driven by the government's transformation effort.

Supply Chain Analysis-Precision Oncology Market

• R&D: Research and development activities include finding new biomarkers, companion diagnostics, targeted therapeutics, genomics, and molecular studies to develop new and improved therapeutic approaches.
  • Key Players: Roche, AstraZeneca, Novartis
• Clinical Trials and Regulatory Approvals: These processes involve evaluating the precision oncology drug's safety and efficacy and ensuring conformity with healthcare standards and objectives.
  • Key Players: IQVIA, Medpace, Parexel
• Formulation / Final Dosage Preparation: Companies are developing precision oncology formulations that will meet standards of stability, quality, and thermal and dosage-compatibility for the patient population.
  • Key Players: Roche, Pfizer, Merck & Co.
• Patient Support and Services: Patient support programmes provide patients with treatment advice, support to adhere to their treatment, financial support, monitoring and educational support to help patients access treatment and achieve better treatment outcomes.

Competitive Landscape

The precision oncology market comprises pharmaceutical and biotechnology firms as well as healthcare technology providers that focus on precision cancer treatment. Rain Oncology Inc., Strata Oncology, Inc., Repare Therapeutics, Relay Therapeutics, and Exscientia have areas of interest that are centered around the use of targeted therapies, molecular profiling, and AI-powered oncology solutions.

Competition is fueled by the identification of novel biomarkers, molecular characterization of the genome, the discovery of targeted therapies, and computation. Partnerships with firms, research organizations, hospitals, diagnostics, clinical application development, and market penetration benefit. Some of the main challenges are R&D, regulatory, clinical validation, data management, and constant innovation.

Precision Oncology Market Companies

Other Major Key Players

• Rain Oncology Inc.
• Strata Oncology, Inc.
• Repare Therapeutics
• Relay Therapeutics
• Exscientia
• Exact Sciences Corporation

Collaboration Landscape

• In May 2026, Roche signed a deal with PathAI and plans to acquire the company. The agreement helps create the next generation in cancer diagnostic and treatment technologies. (Source: https://www.reuters.com)
• In February 2026, joined forces with Gene+ and MGI to promote genomic testing quality and to explore the development of precision oncology technologies. The hallmark project of the partnership is to build a robust genomics-to-functional treatments delivery system. (Source: https://global-mgitech.com)
• In January 2026, SOPHiA GENETICS became a strategic partner with MD Anderson to enhance precision oncology by leveraging its AI-driven genomic insights and analysis. This collaboration will help to optimize cancer diagnosis and treatment using data. (Source: https://www.biopharminternational.com)

Recent Developments

• In April 2023, the Agilent SureSelect Cancer CGP Assay, created for somatic variant profiling for a variety of solid tumor types was launched by Agilent Technologies Inc. The design of the pan-cancer assay is based on an NGS panel of 679 genes that have been carefully selected from the world's top cancer datasets in collaboration with important clinical cancer researchers
• In April 2023, with the use of innovative molecular profiling techniques that direct patient selection and participation, Flare Therapeutics and Caris Life Sciences have established a strategic partnership to push the precision oncology pipeline approaches across five of Flare's therapeutic programs into clinical trials.
• In March 2023, two novel wholly-owned precision oncology development candidates, EXS73565 ('565), a MALT1 protease inhibitor, and EXS74539 ('539), an LSD1 inhibitor, were disclosed by Exscientia plc. These substances have undergone meticulous design in order to increase the potential for patient benefit and address intricate design problems that might reduce the likelihood of success for other substances in development. In the second half of 2023, the company hopes to offer an update on clinical development plans utilizing Exscientia's personalized medicine platform. IND-enabling investigations are now being conducted.
• In June 2022, Turning Point Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center announced a strategic collaboration for research and development towards the expansion of the evaluation of two investigational small molecules of Turning Point that are focused on precision medicine targets well known in oncology.

Segments Covered in the Report:

By Product

• Diagnostics
• Therapeutics

By Cancer Type

• Breast cancer
• Colorectal cancer
• Lung cancer
• Blood Cancer
• Prostate Cancer
• Others

By End-Use

• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Healthcare Data Companies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa